Annovis Bio (ANVS) said Tuesday it was granted a US patent for methods to treat and prevent acute brain or nerve injuries using buntanetap.

The newly issued patent is based on buntanetap's ability to reduce neurotoxicity and address neurodegenerative processes, making it applicable to conditions like stroke, ischemia, traumatic brain injury, and micro infarcts, the company said.

With the US patent, Annovis Bio said it now holds global protection for buntanetap to treat acute neurodegenerative disorders, following similar patents granted in the European Union, Japan, and worldwide.

Price: 4.79, Change: +0.02, Percent Change: +0.42